Skip to main content
Premium Trial:

Request an Annual Quote

Prescient Medicine Acquires AutoGenomics

NEW YORK (GenomeWeb) – Prescient Medicine Holdings said today that it has acquired privately held molecular diagnostics firm AutoGenomics for an undisclosed amount.

AutoGenomics, based on Carlsbad, California, has developed and commercialized the Infiniti platform, a US Food and Drug Administration 510(k)-exempt automated microarray-based diagnostic system with applications in personalized medicine, pain management, cardiovascular health, mental health, women's health, oncology, infectious diseases, and genetic disorders.

Prescient Medicine said that the acquisition will enable it to specifically further the development and commercialization of the Infiniti Neural Response Panel, a diagnostic test to identify patients who may be at risk for opioid use disorder, building upon prior collaborative work by the companies.

The panel identifies genetic mutations involved in the brain's reward pathways associated with increased risk of opioid use disorder. The FDA granted the panel a breakthrough device designation last summer. Prescient and AutoGenomics intend to pursue a de novo premarket submission for the panel, and Prescient plans to market it to physicians as a product called LifeKit Predict.

Hummelstown, Pennsylvania-based Prescient said that the acquisition also includes the entire Infiniti product portfolio including the suite of Infiniti analyzers and a menu of more than 65 molecular diagnostic tests for various diseases, complementing Prescient's LifeKit diagnostic product line.

"Acquiring AutoGenomics provides a robust platform which will accelerate our efforts and advance our delivery of novel diagnostic solutions designed to address the most pressing issues in healthcare, including the opioid crisis," Prescient Medicine CEO Keri Donaldson said in a statement. "The combination of the AutoGenomics platform and Prescient Medicine's existing toxicology and pharmacogenomic solutions allows us to immediately deliver high-value, enhanced services to both firms' existing clients and the market."

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.